Elsevier

Clinical Colorectal Cancer

Volume 8, Issue 4, October 2009, Pages 207-214
Clinical Colorectal Cancer

Original Contribution
Gene Expression Profiles as Predictors of Poor Outcomes in Stage II Colorectal Cancer: A Systematic Review and Meta-analysis

https://doi.org/10.3816/CCC.2009.n.035Get rights and content

Abstract

Purpose

The use of adjuvant therapy in stage II colorectal cancer (CRC) remains controversial. There is a need to identify more effective predictors than the traditional staging system to aid therapeutic decision-making. We performed a systematic review and meta-analysis of gene expression profiles (GEPs) to assess their utility for risk stratification and prediction of poor outcomes in stage II CRC.

Patients and Methods

We performed a comprehensive literature search through December 2007. Studies were included if they reported GEP-based assays in patients with stage II CRC, and either subsequent cancer recurrence or death within 3 years. The prognostic likelihood ratio (LR) and odds ratio (OR) were calculated with 95% confidence intervals and pooled using the fixed-effects method. The weighted average sensitivity, specificity, and accuracy were also reported.

Results

Eight cohorts involving 271 patients contributed to the analysis. The average accuracy, sensitivity, and specificity were 81.9%, 76.2%, and 84.5%, respectively, with a prognostic LR of 4.7 (95% CI, 3.2-6.8) and a prognostic OR of 15.1 (95% CI, 7.9-28.6). No evidence for significant interstudy heterogeneity was noted in either analysis. Subgroup analysis found no difference in results for the prediction of cancer recurrence or death.

Conclusion

This analysis demonstrates the promising potential of using GEP assays as predictors of poor outcomes in stage II CRC, such as cancer recurrence or death. To maximize their utility and availability, further studies will be needed to identify and validate specific gene signatures for poor prognosis in stage II CRC.

References (70)

  • D Chowdary et al.

    Prognostic gene expression signatures can be measured in tissues collected in RNAlater preservative

    J Mol Diagn

    (2006)
  • M-Y Kim et al.

    Recurrent genomic alterations with impact on survival in colorectal cancer identified by genome-wide array comparative genomic hybridization

    Gastroenterology

    (2006)
  • A Jemal et al.

    Cancer Statistics, 2008

    CA Cancer J Clin

    (2008)
  • RT Greenlee et al.

    Cancer statistics, 2000

    CA Cancer J Clin

    (2000)
  • M Saltz et al.

    Adjuvant treatment of colorectal cancer

    Annu Rev Med

    (1997)
  • CG Moertel et al.

    Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma

    N Engl J Med

    (1990)
  • N Wolmark et al.

    Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04

    J Clin Oncol

    (1999)
  • CG Moertel et al.

    Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report

    Ann Intern Med

    (1995)
  • AB Benson et al.

    American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer

    J Clin Oncol

    (2004)
  • A Figueredo et al.

    Adjuvant therapy for stage II colon cancer: A systematic review from the Cancer Care Ontario Program in Evidence-Based Care's Gastrointestinal Cancer Disease Site Group

    J Clin Oncol

    (2004)

  • Adjuvant chemotherapy versus observation in patients with colorectal cancer: A randomised study

    Lancet

    (2007)
  • T André et al.

    Current issues in adjuvant treatment of stage II colon cancer

    Ann Surg Oncol

    (2006)
  • PG Johnston

    Stage II colorectal cancer: To treat or not to treat

    Oncologist

    (2005)
  • J Quackenbush

    Microarray analysis and tumor classification

    N Engl J Med

    (2006)
  • LJ van 't Veer et al.

    Gene expression profiling predicts clinical outcome of breast cancer

    Nature

    (2002)
  • MJ van de Vijver et al.

    A gene-expression signature as a predictor of survival in breast cancer

    N Engl J Med

    (2002)
  • Z Sun et al.

    Non-overlapping and non-cell-type-specific gene expression signatures predict lung cancer survival

    J Clin Oncol

    (2008)
  • DG Beer et al.

    Gene-expression profiles predict survival of patients with lung adenocarcinoma

    Nat Med

    (2002)
  • GV Glinsky et al.

    Gene expression profiling predicts clinical outcome of prostate cancer

    J Clin Invest

    (2004)
  • J Lapointe et al.

    Gene expression profiling identifies clinically relevant subtypes of prostate cancer

    Proc Natl Acad Sci USA

    (2004)
  • IS Lossos et al.

    Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes

    N Engl J Med

    (2004)
  • A Rosenwald et al.

    The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

    N Engl J Med

    (2002)
  • A Barrier et al.

    Stage III colon cancer prognosis prediction by gene expression profiling

    J Clin Oncol

    (2007)
  • Y Wang et al.

    Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer

    J Clin Oncol

    (2004)
  • A Barrier et al.

    Gene expression profiling of nonneoplastic mucosa may predict clinical outcome of colon cancer patients

    Dis Colon Rectum

    (2005)

    • Cited by (0)

    This summary may include the discussion of investigational and/or unlabeled uses of drugs and/or devices that may not be approved by the FDA.

    Electronic forwarding or copying is a violation of US and International Copyright Laws.

    Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by CIG Media Group, LP, ISSN #1533-0028, provided the appropriate fee is paid directly to Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA. www.copyright.com 978-750-8400.

    *

    Posthumous

    View full text
    Copyright © 2009 Elsevier Inc. All rights reserved.